← back to search

Maryam Fouladi

University of Cincinnati · US
Area of research
Genetics · Neurology
Research interest
Maryam Fouladi, MD, MSc, FRCP, is a pediatric neuro-oncologist, co-executive director of the pediatric neuro-oncology program at Nationwide Children’s Hospital, and a Professor of Pediatrics at the Ohio State University College of Medicine. Dr. Fouladi is an internationally recognized expert in pediatric brain tumors, and is particularly renowned for her work in phase I clinical trials. She is the founding director of CONNECT, an international consortium focused on developing and testing novel therapies in early phase clinical trials. Fouladi’s primary research interest focus on brain stem gliomas (DIPG) and is the founding Chair of The International Diffuse Intrinsic Pontine Glioma (DIPG)/diffuse midline glioma (DMG) Registry. She has authored or co-authored over 140 peer-reviewed publications in leading medical journals. In addition to her roles at Nationwide Children’s and Ohio State Wexner Medical Center, Dr. Fouladi serves as the Chair of the Collaborative Network for Neuro-Oncology Clinical Trials and CNS Committee of the Children’s Oncology Group. Prior to coming to Nationwide Children’s, Dr. Fouladi served as medical director of the Brain Tumor Center at Cincinnati Children’s Hospital and was also a full professor and the Marjory J. Johnson Endowed Chair in Brain Tumor Translational Research. She received her medical degree from the University of Toronto, and completed her pediatric residency and hematology/oncology fellowship at The Hospital for Sick Children in Toronto. She completed her neuro-oncology fellowship training at St. Jude Children’s Research Hospital followed by additional training in the Molecular Pharmacology Department at St. Jude Children’s Hospital.
h-index
75
citations
23,712
works
477
NIH funding
primary concept
Medicine
email

Recent publications

Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children’s Oncology Group
Neuro-Oncology 2025cited by 17position: middledoi
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.
2025cited by 14position: contributordoi
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4
Neuro-Oncology 2025cited by 10position: middledoi
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group.
2025cited by 8position: contributordoi
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study.
2025cited by 5position: contributordoi
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
2025cited by 4position: contributordoi
IMMU-79. An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13
Neuro-Oncology 2025cited by 0position: middledoi
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions
Neuro-Oncology 2024cited by 23position: middledoi
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
JAMA Oncology 2024cited by 17position: middledoi
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
Journal of Clinical Oncology 2024cited by 11position: middledoi
Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.
2024cited by 8position: contributordoi
Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward.
2024cited by 6position: contributordoi
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
2024cited by 5position: contributordoi
LGG-05. REPORT ON PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-029B, A PROSPECTIVE PHASE 2 CLINICAL TRIAL OF SELUMETINIB IN TREATING YOUNG PATIENTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA: NEW RESULTS ON STRATA 2, 5, AND 6 WITH UPDATED LONG-TERM SURVIVAL OUTCOMES ON STRATA 1, 3, AND 4
Neuro-Oncology 2024cited by 2position: middledoi
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer
Journal of Clinical Oncology 2023cited by 47position: middledoi
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
2023cited by 44position: contributordoi
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group
Neuro-Oncology 2023cited by 9position: middledoi
Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks
Frontiers in Oncology 2023cited by 2position: middledoi
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report.
2022cited by 42position: contributordoi
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
2022cited by 40position: contributordoi
Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
2022cited by 27position: contributordoi
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Neuro-Oncology Advances 2022cited by 19position: middledoi
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
2022cited by 19position: contributordoi
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group.
UCL Discovery (University College London) 2022cited by 15position: middledoi
A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors
International Journal of Radiation Oncology*Biology*Physics 2022cited by 15position: middledoi
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
2022cited by 13position: contributordoi
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study
Neuro-Oncology 2022cited by 11position: middledoi
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data.
2022cited by 10position: contributordoi
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
2022cited by 10position: contributordoi
Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report.
2022cited by 9position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Arzu Onar‐Thomas · Cancer Research And Biostatistics20 papers (2013–2025)Jason Fangusaro · Winship Cancer Institute19 papers (2013–2025) · 18 papers (2019–2025)Ian F. Pollack · University of Pittsburgh16 papers (2012–2025)Amar Gajjar · Mills Peninsula Health Services14 papers (2013–2025)Roger J. Packer · Jefferson Hospital for Neuroscience13 papers (2012–2024)Sarah Leary · Neurological Surgery13 papers (2018–2025)Ira J. Dunkel · National Cancer Institute11 papers (2016–2025)Shengjie Wu · St. Jude Children's Research Hospital11 papers (2013–2022)Stewart Goldman · Phoenix College10 papers (2012–2021)Tina Young Poussaint · Boston Children's Hospital9 papers (2013–2025)Girish Dhall · Children's of Alabama9 papers (2016–2022)Sridharan Gururangan · Deltagen (United States)8 papers (2013–2025)Lindsay Kilburn · Columbia University Irving Medical Center8 papers (2017–2025)Eugene Hwang · Center for Cancer and Blood Disorders7 papers (2018–2025)Ibrahim Qaddoumi · Tennessee Oncology7 papers (2017–2025)James M. Boyett · University of Illinois Chicago6 papers (2013–2021)L. Austin Doyle · National Cancer Institute6 papers (2014–2022)Paul G. Fisher · Mount Sinai Hospital6 papers (2015–2024)Azra H. Ligon · Harvard University6 papers (2017–2025)